

Alzheimer's Disease Diagnosis by Spectroscopy. Accurate and Non-Invasive Medical Device for the Diagnosis of Early Stage Alzheimer's Disease.

<https://www.neurodegenerationresearch.eu/survey/alzheimer%20s-disease-diagnosis-by-spectroscopy-accurate-and-non-invasive-medical-device-for-the-diagnosis-of-early-stage-alzheimers-disease/>

Principal Investigators

Institution

Contact information of lead PI

Country

European Commission

Title of project or programme

Alzheimer's Disease Diagnosis by Spectroscopy. Accurate and Non-Invasive Medical Device for the Diagnosis of Early Stage Alzheimer's Disease.

Source of funding information

European Commission Horizon 2020

Total sum awarded (Euro)

€ 50,000

Start date of award

01/07/2015

Total duration of award in years

0.3

Keywords

Research Abstract

Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer's Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient's brain after being injected with a radioactive marker (cost of €1500) which can cause major allergic reactions. The other method analyzes the cerebrospinal fluid, which requires performing the patient a lumbar puncture. This procedure (relatively expensive, €400) can cause severe headaches, temporary pain of numbness to legs, infections and bleeding into the spinal canal. There are more than 30

million people living with AD in Europe and more than 7 million people that have not received a diagnostic due to the cost and side effects of the current techniques. Without diagnostic, patients lack of a proper treatment that improves patients life quality ameliorating the symptoms of the disease. The earlier the diagnosis, the earlier the treatment delaying nursery admission. Our solution consists of performing RS onto a sample of blood plasma. It is not invasive, has absolutely no side effects and an estimated selling price of €100. Our solution, making AD diagnosis more affordable, can produce net saving of €2,8bn to the European Healthcare system only delaying institutionalization. Our aim is to bring our solution into the market as a reference diagnostic method for screening patients for Alzheimer's Disease. Alzheimer Disease is a huge problem that Europe needs to address due to the aging population. By 2050, 50% of the total European population will be over 65 years old and more importantly, 1 out 3 will suffer from Alzheimer's Disease.

Further information available at:

Types:

Investments < €500k

Member States:

European Commission

Diseases:

N/A

Years:

2016

Database Categories:

N/A

Database Tags:

N/A